Cargando…

The Indigenous Australian Human Papillomavirus (HPV) Cohort Study 2, Continuation for 5 to 10 Years: Protocol for a Longitudinal Study

BACKGROUND: Human papillomavirus (HPV) infection, a common sexually transmitted disease, is associated with cancers of the cervix, vulva, vagina, penis, anus, and head and neck. Oropharyngeal squamous cell carcinoma (OPSCC; throat cancer) is a type of cancer involving the head and neck area that is...

Descripción completa

Detalles Bibliográficos
Autores principales: Hedges, Joanne, Sethi, Sneha, Garvey, Gail, Whop, Lisa J, Canfell, Karen, Dodd, Zell, Larkins, Priscilla, Antonsson, Annika, Smith, Megan A, Mittinty, Murthy, Leane, Catherine, Reid, Nicolas, Ooi, Eng H, Ju, Xiangqun, Logan, Richard, Jamieson, Lisa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: JMIR Publications 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10233440/
https://www.ncbi.nlm.nih.gov/pubmed/37195752
http://dx.doi.org/10.2196/44593
_version_ 1785052234204053504
author Hedges, Joanne
Sethi, Sneha
Garvey, Gail
Whop, Lisa J
Canfell, Karen
Dodd, Zell
Larkins, Priscilla
Antonsson, Annika
Smith, Megan A
Mittinty, Murthy
Leane, Catherine
Reid, Nicolas
Ooi, Eng H
Ju, Xiangqun
Logan, Richard
Jamieson, Lisa
author_facet Hedges, Joanne
Sethi, Sneha
Garvey, Gail
Whop, Lisa J
Canfell, Karen
Dodd, Zell
Larkins, Priscilla
Antonsson, Annika
Smith, Megan A
Mittinty, Murthy
Leane, Catherine
Reid, Nicolas
Ooi, Eng H
Ju, Xiangqun
Logan, Richard
Jamieson, Lisa
author_sort Hedges, Joanne
collection PubMed
description BACKGROUND: Human papillomavirus (HPV) infection, a common sexually transmitted disease, is associated with cancers of the cervix, vulva, vagina, penis, anus, and head and neck. Oropharyngeal squamous cell carcinoma (OPSCC; throat cancer) is a type of cancer involving the head and neck area that is rapidly increasing across the globe. There are higher rates of OPSCC among Indigenous populations relative to non–Indigenous Australian populations, although the HPV-attributable fraction remains unknown. For the first time at a global level, we plan to extend an Indigenous Australian adult cohort to monitor, screen, and ultimately prevent HPV-associated OPSCC and to undertake extensive cost-effectiveness modelling around HPV vaccination. OBJECTIVE: This study aims to (1) extend follow-up to a minimum of 7 years post recruitment to describe the prevalence, incidence, clearance, and persistence of oral HPV infection; and (2) conduct clinical examinations of the head and neck, oral cavity, and oropharynx and collect saliva samples for early-stage OPSCC testing. METHODS: We will continue to implement a longitudinal design for the next study phase, where we will ascertain the prevalence, incidence, clearance, and persistence of oral HPV infection at 48, 60, and 72 months; undertake clinical examinations/saliva assessments to detect early-stage OPSCC; and refer for treatment. The primary outcome measures are changes in oral HPV infection status, biomarker measures of early HPV-related cancer, and clinical evidence of early-stage OPSCC. RESULTS: Participant 48-month follow-up will commence in January 2023. The first results are expected to be submitted for publication 1 year after 48-month follow-up begins. CONCLUSIONS: Our findings have potential to change the way in which OPSCC among Australian Indigenous adults is managed, with desired impacts including cost-savings on expensive cancer treatments; improved nutritional, social, and emotional outcomes; and improved quality of life for both Indigenous adults and the Indigenous community more broadly. Continuing a large, representative Indigenous adult cohort to track oral HPV infection and monitor early OPSCC is essential to yield critical information to include in the management armamentarium of health and well-being recommendations for Australia’s First Nations. INTERNATIONAL REGISTERED REPORT IDENTIFIER (IRRID): PRR1-10.2196/44593
format Online
Article
Text
id pubmed-10233440
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher JMIR Publications
record_format MEDLINE/PubMed
spelling pubmed-102334402023-06-02 The Indigenous Australian Human Papillomavirus (HPV) Cohort Study 2, Continuation for 5 to 10 Years: Protocol for a Longitudinal Study Hedges, Joanne Sethi, Sneha Garvey, Gail Whop, Lisa J Canfell, Karen Dodd, Zell Larkins, Priscilla Antonsson, Annika Smith, Megan A Mittinty, Murthy Leane, Catherine Reid, Nicolas Ooi, Eng H Ju, Xiangqun Logan, Richard Jamieson, Lisa JMIR Res Protoc Protocol BACKGROUND: Human papillomavirus (HPV) infection, a common sexually transmitted disease, is associated with cancers of the cervix, vulva, vagina, penis, anus, and head and neck. Oropharyngeal squamous cell carcinoma (OPSCC; throat cancer) is a type of cancer involving the head and neck area that is rapidly increasing across the globe. There are higher rates of OPSCC among Indigenous populations relative to non–Indigenous Australian populations, although the HPV-attributable fraction remains unknown. For the first time at a global level, we plan to extend an Indigenous Australian adult cohort to monitor, screen, and ultimately prevent HPV-associated OPSCC and to undertake extensive cost-effectiveness modelling around HPV vaccination. OBJECTIVE: This study aims to (1) extend follow-up to a minimum of 7 years post recruitment to describe the prevalence, incidence, clearance, and persistence of oral HPV infection; and (2) conduct clinical examinations of the head and neck, oral cavity, and oropharynx and collect saliva samples for early-stage OPSCC testing. METHODS: We will continue to implement a longitudinal design for the next study phase, where we will ascertain the prevalence, incidence, clearance, and persistence of oral HPV infection at 48, 60, and 72 months; undertake clinical examinations/saliva assessments to detect early-stage OPSCC; and refer for treatment. The primary outcome measures are changes in oral HPV infection status, biomarker measures of early HPV-related cancer, and clinical evidence of early-stage OPSCC. RESULTS: Participant 48-month follow-up will commence in January 2023. The first results are expected to be submitted for publication 1 year after 48-month follow-up begins. CONCLUSIONS: Our findings have potential to change the way in which OPSCC among Australian Indigenous adults is managed, with desired impacts including cost-savings on expensive cancer treatments; improved nutritional, social, and emotional outcomes; and improved quality of life for both Indigenous adults and the Indigenous community more broadly. Continuing a large, representative Indigenous adult cohort to track oral HPV infection and monitor early OPSCC is essential to yield critical information to include in the management armamentarium of health and well-being recommendations for Australia’s First Nations. INTERNATIONAL REGISTERED REPORT IDENTIFIER (IRRID): PRR1-10.2196/44593 JMIR Publications 2023-05-17 /pmc/articles/PMC10233440/ /pubmed/37195752 http://dx.doi.org/10.2196/44593 Text en ©Joanne Hedges, Sneha Sethi, Gail Garvey, Lisa J Whop, Karen Canfell, Zell Dodd, Priscilla Larkins, Annika Antonsson, Megan A Smith, Murthy Mittinty, Catherine Leane, Nicolas Reid, Eng H Ooi, Xiangqun Ju, Richard Logan, Lisa Jamieson. Originally published in JMIR Research Protocols (https://www.researchprotocols.org), 17.05.2023. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work, first published in JMIR Research Protocols, is properly cited. The complete bibliographic information, a link to the original publication on https://www.researchprotocols.org, as well as this copyright and license information must be included.
spellingShingle Protocol
Hedges, Joanne
Sethi, Sneha
Garvey, Gail
Whop, Lisa J
Canfell, Karen
Dodd, Zell
Larkins, Priscilla
Antonsson, Annika
Smith, Megan A
Mittinty, Murthy
Leane, Catherine
Reid, Nicolas
Ooi, Eng H
Ju, Xiangqun
Logan, Richard
Jamieson, Lisa
The Indigenous Australian Human Papillomavirus (HPV) Cohort Study 2, Continuation for 5 to 10 Years: Protocol for a Longitudinal Study
title The Indigenous Australian Human Papillomavirus (HPV) Cohort Study 2, Continuation for 5 to 10 Years: Protocol for a Longitudinal Study
title_full The Indigenous Australian Human Papillomavirus (HPV) Cohort Study 2, Continuation for 5 to 10 Years: Protocol for a Longitudinal Study
title_fullStr The Indigenous Australian Human Papillomavirus (HPV) Cohort Study 2, Continuation for 5 to 10 Years: Protocol for a Longitudinal Study
title_full_unstemmed The Indigenous Australian Human Papillomavirus (HPV) Cohort Study 2, Continuation for 5 to 10 Years: Protocol for a Longitudinal Study
title_short The Indigenous Australian Human Papillomavirus (HPV) Cohort Study 2, Continuation for 5 to 10 Years: Protocol for a Longitudinal Study
title_sort indigenous australian human papillomavirus (hpv) cohort study 2, continuation for 5 to 10 years: protocol for a longitudinal study
topic Protocol
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10233440/
https://www.ncbi.nlm.nih.gov/pubmed/37195752
http://dx.doi.org/10.2196/44593
work_keys_str_mv AT hedgesjoanne theindigenousaustralianhumanpapillomavirushpvcohortstudy2continuationfor5to10yearsprotocolforalongitudinalstudy
AT sethisneha theindigenousaustralianhumanpapillomavirushpvcohortstudy2continuationfor5to10yearsprotocolforalongitudinalstudy
AT garveygail theindigenousaustralianhumanpapillomavirushpvcohortstudy2continuationfor5to10yearsprotocolforalongitudinalstudy
AT whoplisaj theindigenousaustralianhumanpapillomavirushpvcohortstudy2continuationfor5to10yearsprotocolforalongitudinalstudy
AT canfellkaren theindigenousaustralianhumanpapillomavirushpvcohortstudy2continuationfor5to10yearsprotocolforalongitudinalstudy
AT doddzell theindigenousaustralianhumanpapillomavirushpvcohortstudy2continuationfor5to10yearsprotocolforalongitudinalstudy
AT larkinspriscilla theindigenousaustralianhumanpapillomavirushpvcohortstudy2continuationfor5to10yearsprotocolforalongitudinalstudy
AT antonssonannika theindigenousaustralianhumanpapillomavirushpvcohortstudy2continuationfor5to10yearsprotocolforalongitudinalstudy
AT smithmegana theindigenousaustralianhumanpapillomavirushpvcohortstudy2continuationfor5to10yearsprotocolforalongitudinalstudy
AT mittintymurthy theindigenousaustralianhumanpapillomavirushpvcohortstudy2continuationfor5to10yearsprotocolforalongitudinalstudy
AT leanecatherine theindigenousaustralianhumanpapillomavirushpvcohortstudy2continuationfor5to10yearsprotocolforalongitudinalstudy
AT reidnicolas theindigenousaustralianhumanpapillomavirushpvcohortstudy2continuationfor5to10yearsprotocolforalongitudinalstudy
AT ooiengh theindigenousaustralianhumanpapillomavirushpvcohortstudy2continuationfor5to10yearsprotocolforalongitudinalstudy
AT juxiangqun theindigenousaustralianhumanpapillomavirushpvcohortstudy2continuationfor5to10yearsprotocolforalongitudinalstudy
AT loganrichard theindigenousaustralianhumanpapillomavirushpvcohortstudy2continuationfor5to10yearsprotocolforalongitudinalstudy
AT jamiesonlisa theindigenousaustralianhumanpapillomavirushpvcohortstudy2continuationfor5to10yearsprotocolforalongitudinalstudy
AT hedgesjoanne indigenousaustralianhumanpapillomavirushpvcohortstudy2continuationfor5to10yearsprotocolforalongitudinalstudy
AT sethisneha indigenousaustralianhumanpapillomavirushpvcohortstudy2continuationfor5to10yearsprotocolforalongitudinalstudy
AT garveygail indigenousaustralianhumanpapillomavirushpvcohortstudy2continuationfor5to10yearsprotocolforalongitudinalstudy
AT whoplisaj indigenousaustralianhumanpapillomavirushpvcohortstudy2continuationfor5to10yearsprotocolforalongitudinalstudy
AT canfellkaren indigenousaustralianhumanpapillomavirushpvcohortstudy2continuationfor5to10yearsprotocolforalongitudinalstudy
AT doddzell indigenousaustralianhumanpapillomavirushpvcohortstudy2continuationfor5to10yearsprotocolforalongitudinalstudy
AT larkinspriscilla indigenousaustralianhumanpapillomavirushpvcohortstudy2continuationfor5to10yearsprotocolforalongitudinalstudy
AT antonssonannika indigenousaustralianhumanpapillomavirushpvcohortstudy2continuationfor5to10yearsprotocolforalongitudinalstudy
AT smithmegana indigenousaustralianhumanpapillomavirushpvcohortstudy2continuationfor5to10yearsprotocolforalongitudinalstudy
AT mittintymurthy indigenousaustralianhumanpapillomavirushpvcohortstudy2continuationfor5to10yearsprotocolforalongitudinalstudy
AT leanecatherine indigenousaustralianhumanpapillomavirushpvcohortstudy2continuationfor5to10yearsprotocolforalongitudinalstudy
AT reidnicolas indigenousaustralianhumanpapillomavirushpvcohortstudy2continuationfor5to10yearsprotocolforalongitudinalstudy
AT ooiengh indigenousaustralianhumanpapillomavirushpvcohortstudy2continuationfor5to10yearsprotocolforalongitudinalstudy
AT juxiangqun indigenousaustralianhumanpapillomavirushpvcohortstudy2continuationfor5to10yearsprotocolforalongitudinalstudy
AT loganrichard indigenousaustralianhumanpapillomavirushpvcohortstudy2continuationfor5to10yearsprotocolforalongitudinalstudy
AT jamiesonlisa indigenousaustralianhumanpapillomavirushpvcohortstudy2continuationfor5to10yearsprotocolforalongitudinalstudy